ClinicalTrials.gg
Active, not recruitingNCT05967000PhenomenonUpdated Aug 1, 2023

Evaluating a Preventive Heart Health Programme for Women at Midlife

An observational study in Cardiovascular Disease and Menopause, sponsored by Alexandra Hospital. Active, not recruiting at 1 site in Singapore. Open to female participants aged 45 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-08-01.

Sponsored by Alexandra Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
120
Ages
45 Years to 65 Years
Sex
Female
01

Study summary

This study examines the factors that limit or support the implementation of a pilot heart health program for perimenopausal women. The investigators evaluate the effectiveness of this program in raising awareness and promoting behavior change to maintain cardiovascular health.

Read the detailed description

Cardiovascular disease (CVD) is the leading cause of mortality among women. Heart-related conditions are responsible for the death of one out of every three women. In Singapore, CVD in women causes more morbidity and mortality than breast and cervical cancer. The burden will be exacerbated by Singapore's aging population and the longer life expectancy of women compared to men. Primary and secondary prevention strategies are implemented to reduce the overall impact of CVD on public health. Women who have traditional risk factors are at a greater risk of experiencing heart attacks compared to men with comparable risk factors. Additional risks specific to women include a history of pregnancy complications, breast cancer, and premature menopause. CVDs in women are frequently overlooked in terms of diagnosis and treatment.

Menopause is a phase in a woman's life that brings about significant changes to both her reproductive organs and her physical and psychological well-being. Management issues encompass a spectrum of concerns, including immediate symptoms like insomnia and palpitations, intermediate concerns related to bone health, and long-term considerations associated with the development of cardiovascular disease. The American Heart Association (AHA) provides guidelines for multidisciplinary care aimed at preventing cardiovascular disease (CVD) in women. Countries like Canada have established specialized organizations to address this issue. Collaborative clinics involving cardiologists, gynecologists, and women's heart centers are crucial, even for women who are generally healthy.

The objective of this study is to examine the factors that limit or support the implementation of a preventive heart health program for perimenopausal women. Additionally, the investigators aim to evaluate the effectiveness of our pilot women's health program in raising awareness and promoting behavior change to maintain cardiovascular health.

02

Conditions studied

  • Cardiovascular Disease
  • Menopause

Keywords

  • preventive cardiology
  • menopause
  • implementation
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 120 is below the median of 534 across 1,577 observational studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Alexandra Hospital is the lead sponsor of 8 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women going through the menopause transition with risk factors for CVD or pre-existing CVD.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 45-65 years at risk for cardiovascular disease or with pre-existing cardiovascular disease.
  • English speaking

Exclusion criteria

Exclusion Criteria:

  • Pregnant women
  • Unable to provide
  • Women out of the menopause transition phase of 45-65 years of age.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • Women at midlife

    Women aged 45-65 years with risk factors or pre-existing CVD

    Other: Preventive heart health and menopause programme

Interventions

  • OtherPreventive heart health and menopause programme

    This is a one-stop women's heart and menopausal service in a public hospital led by cardiologists and gynaecologists with a multidisciplinary team. Pre-existing speciality care and services are repackaged, and clinic workflows are reworked to provide more streamlined, convenient, and integrated care. Services encompass: * Individualised risk assessment, screening, diagnosis, and treatment of CVD. * Lifestyle education, adjustment, stress management, and counselling. * Smoking cessation programs. * Bone health screening, mammogram with access to our co-located gynaecologists and hormone replacement therapy. * Virtual consults and health coaching.

06

What researchers measure

Primary outcomes

  1. Reach of the programme

    This a part of the RE-AIM comprehensive method for programme evaluation. This is measured via participation rate which is the number of eligible women recruited (numerator) divided by the number of eligible women screened for the programme (denominator

    Time frame: 1 year

  2. Effectiveness of the programme

    This a part of the RE-AIM comprehensive method for programme evaluation. This is measured via the GPAQ (Global physical activity questionnaire)

    Time frame: 1 year

  3. Effectiveness of the programme

    This a part of the RE-AIM comprehensive method for programme evaluation. This is measured via the Utian Quality of life scale.

    Time frame: 1 year

  4. Adoption of the programme

    This a part of the RE-AIM comprehensive method for programme evaluation. This is measured via qualitative interviews to assess whether healthcare providers are accepting of the intervention and can sustain the change.

    Time frame: 1 year

  5. Implementation of the programme

    This will be measured as counts from clinic visits

    Time frame: 1 year

Secondary outcomes

  1. Anthropometric measurements

    Weight and height will be combined to report BMI in kg/m\^2

    Time frame: 1 year

  2. Blood pressure

    Office blood pressure measurements

    Time frame: 1 year

  3. Blood biomarkers

    Hba1c

    Time frame: 1 year

  4. Blood biomarkers

    Lipid profile

    Time frame: 1 year

  5. Blood biomarkers

    Vitamin D levels

    Time frame: 1 year

  6. Surveys

    Semi structure interviews will be conducted and analysed via reflexive thematic approach.

    Time frame: At the end of the study at 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Sep 2024, 15 months after the start.

Of 583 non-industry observational studies under Cardiovascular Diseases, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 196. This study's planned 15 months is below that.

Counting every sponsor, half of 667 studies reached it within 62 months; a quarter within 24 and three quarters within 192.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2023
First posted
Aug 1, 2023
StartActual
Jun 1, 2023
Primary completionEst.
Sep 1, 2024
CompletionEst.
Dec 31, 2024
Last update
Aug 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05967000
Lead sponsor
Alexandra Hospital
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Jun 1, 2023
Primary completion
Sep 1, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Aug 1, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion